Akari Therapeutics Plc Overview

Akari Therapeutics Plc Research & Development

Research & Development expenses for AKTX.

Quarterly R&D Expenses

$1.46M

↑ 79.46% YoY

As of Mar 31, 2026

Annual R&D Expenses (TTM)

$3.46M

↓ 37.24% YoY

Trailing 12 months ending Mar 31, 2026

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin